Nasim Mavaddat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nasim Mavaddat has a total of 845 co-authors. Here are the top co-authors by number of shared publications:
- Douglas F. Easton
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge , Cambridge CB1 8RN
37 shared publications - Antonis C. Antoniou
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge , Cambridge CB1 8RN
19 shared publications - Elinor J. Sawyer
School of Cancer & Pharmaceutical Sciences, Comprehensive Cancer Centre, Guy’s Campus, King’s College London, London, UK
19 shared publications - Marjanka K. Schmidt
Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, 1066 CX, The Netherlands.
18 shared publications - Christos Petridis
Breast Cancer Genetics, King’s College London, London, United Kingdom
17 shared publications - Jasmine Timbres
Breast Cancer Genetics, King’s College London, London, United Kingdom
17 shared publications
Latest Publications
- Open Access
- 30 March 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 134 (10) , 1479-1487
Natural menopause, menarche and breast cancer risk in BRCA1 and BRCA2 pathogenic variant carriers: a Mendelian randomization analysis
Background: The influence of age at menarche (AAM) and age at natural menopause (ANM) on breast cancer (BC) risk in BRCA1 and BRCA2 germline pathogenic variant (PV) carriers is uncertain. Observational studies are prone to bias and have limited statistical power. Mendelian randomization (MR) minimises bias and may be used to examine causal effects. Methods: Two-sample and age-specific MR analyses for BC were performed. For AAM, two-sample multivariable MR and mediation analyses to account for the confounding effect of body mass index (BMI), were undertaken. Results: Genetic scores for ANM and AAM predicted the respective traits in PV carriers. Inverse-variance weighted hazard ratios (HR) for genetically predicted ANM per-year were HR = 0.99 (95%CI:0.97–1.01, p = 0.45) and HR = 1.04 (95% CI:1.01–1.06, p = 0.003) for BRCA1 and BRCA2 PV carriers, respectively. After adjusting for genetic associations with BMI, AAM per-year on BC risk were HR = 0.90 (95%CI:0.83–0.98, p = 0.01) and HR = 0.95 (95%CI:0.86–1.04, p = 0.26) for BRCA1 and BRCA2 carriers, respectively, consistent with a protective effect of later AAM. Discussion: MR analyses support causal associations between ANM and BC risk in BRCA2 , but not BRCA1 , and between AAM and BC risk in BRCA1 and BRCA2 PV carriers. These results may aid risk prediction models and genetic counselling of carriers.
- 30 March 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 134 (10) , 1479-1487
Open AccessNatural menopause, menarche and breast cancer risk in BRCA1 and BRCA2 pathogenic variant carriers: a Mendelian randomization analysis
Background: The influence of age at menarche (AAM) and age at natural menopause (ANM) on breast cancer (BC) risk in BRCA1 and BRCA2 germline pathogenic variant (PV) carriers is uncertain. Observational studies are prone to bias and have limited statistical power. Mendelian randomization (MR) minimises bias and may be used to examine causal effects. Methods: Two-sample and age-specific MR analyses for BC were performed. For AAM, two-sample multivariable MR and mediation analyses to account for the confounding effect of body mass index (BMI), were undertaken. Results: Genetic scores for ANM and AAM predicted the respective traits in PV carriers. Inverse-variance weighted hazard ratios (HR) for genetically predicted ANM per-year were HR = 0.99 (95%CI:0.97–1.01, p = 0.45) and HR = 1.04 (95% CI:1.01–1.06, p = 0.003) for BRCA1 and BRCA2 PV carriers, respectively. After adjusting for genetic associations with BMI, AAM per-year on BC risk were HR = 0.90 (95%CI:0.83–0.98, p = 0.01) and HR = 0.95 (95%CI:0.86–1.04, p = 0.26) for BRCA1 and BRCA2 carriers, respectively, consistent with a protective effect of later AAM. Discussion: MR analyses support causal associations between ANM and BC risk in BRCA2 , but not BRCA1 , and between AAM and BC risk in BRCA1 and BRCA2 PV carriers. These results may aid risk prediction models and genetic counselling of carriers.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model
Supplementary Table S3 shows SNPs and weights for the BCAC PRS313.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model
Supplementary Table S3 shows SNPs and weights for the BCAC PRS313.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model
Supplementary Methods provides details of methodology
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model
Supplementary Methods provides details of methodology
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model
Supplementary Table S1 shows studies and samples used in these analyses
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model
Supplementary Table S1 shows studies and samples used in these analyses
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model
Supplementary Table S2 show the country in which the studies were conducted
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model
Supplementary Table S2 show the country in which the studies were conducted
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model
Supplementary Table S4shows SNPs and weights used in the alternative PRS.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model
Supplementary Table S4shows SNPs and weights used in the alternative PRS.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Table S4. Univariate and multivariate Cox regression models for recurrence-free survival (RFS) and disease-free survival (DFS) after DCIS and continuous ER-positive PRS.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Table S4. Univariate and multivariate Cox regression models for recurrence-free survival (RFS) and disease-free survival (DFS) after DCIS and continuous ER-positive PRS.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Table S1. Genotyped and imputed (not genotyped) SNPs
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Table S1. Genotyped and imputed (not genotyped) SNPs
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table 3 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Univariate and multivariate Cox regression including continuous overall PRS in DCIS and LCIS.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Univariate and multivariate Cox regression including continuous overall PRS in DCIS and LCIS.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 11 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Table S11. Univariate and multivariate Cox regression models comparing risk of developing invasive ipsilateral recurrence after DCIS or LCIS.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 11 from Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Table S11. Univariate and multivariate Cox regression models comparing risk of developing invasive ipsilateral recurrence after DCIS or LCIS.